Kazia Therapeutics LTD (KZIA) — 20-F Filings
All 20-F filings from Kazia Therapeutics LTD. Browse 2 Foreign Annual Report reports with AI-powered summaries and risk analysis.
20-F Filings (2)
-
Kazia's Losses Mount to A$134.8M Amidst Plummeting Licensing Revenue
— Nov 7, 2025 Risk: high
KAZIA THERAPEUTICS LTD reported significant net losses for the fiscal year ended June 30, 2025, totaling A$20.7 million, following losses of A$26.8 million in 2 -
Kazia Therapeutics Files 20-F for FY24
— Nov 15, 2024 Risk: medium
Kazia Therapeutics Ltd. filed its annual 20-F report for the fiscal year ending June 30, 2024. The company, formerly Novogen Ltd., is based in Sydney, NSW, Aust
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX